0001209191-18-024991.txt : 20180416 0001209191-18-024991.hdr.sgml : 20180416 20180416162458 ACCESSION NUMBER: 0001209191-18-024991 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20180412 FILED AS OF DATE: 20180416 DATE AS OF CHANGE: 20180416 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Reynolds Donald Rogers CENTRAL INDEX KEY: 0001687930 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-21990 FILM NUMBER: 18756872 MAIL ADDRESS: STREET 1: C/O WYRICK ROBBINS YATES & PONTON LLP STREET 2: 4101 LAKE BOONE TRAIL, SUITE 300 CITY: RALEIGH STATE: NC ZIP: 27607 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: MATEON THERAPEUTICS INC CENTRAL INDEX KEY: 0000908259 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 133679168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 701 GATEWAY BLVD. STREET 2: SUITE 210 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 BUSINESS PHONE: 650-635-7000 MAIL ADDRESS: STREET 1: 701 GATEWAY BLVD. STREET 2: SUITE 210 CITY: SOUTH SAN FRANCISCO STATE: CA ZIP: 94080 FORMER COMPANY: FORMER CONFORMED NAME: OXIGENE INC DATE OF NAME CHANGE: 19930628 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2018-04-12 0 0000908259 MATEON THERAPEUTICS INC MATN 0001687930 Reynolds Donald Rogers C/O MATEON THERAPEUTICS, INC. 701 GATEWAY BLVD., SUITE 210 SOUTH SAN FRANCISCO CA 94080 1 0 0 0 Common Stock 2018-04-12 4 P 0 250000 A 280000 D Common Stock A Warrants (Right to Buy) 0.40 2018-04-12 4 P 0 125000 A 2018-04-12 2020-04-12 Common Stock 125000 125000 D Common Stock B Warrants (Right to Buy) 0.40 2018-04-12 4 P 0 125000 A Common Stock 125000 125000 D The reported securities are included within one Unit purchased by the reporting person for $50,000 per Unit pursuant to a Subscription Agreement between the reporting person and Mateon Therapeutics, Inc. (the "Company"), dated April 12, 2018 (the "Subscription Agreement"). Each Unit consists of (i) 250,000 shares of Common Stock of the Company, par value $0.01 per share (the "Common Stock"), (ii) an "A" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share and (iii) a "B" warrant to purchase 125,000 shares of Common Stock at an exercise price of $0.40 per share. The Common Stock B Warrants shall become exercisable immediately following the Company's stockholders' approval of an increase in the number of the Company's authorized shares of Common Stock sufficient to cover the number of shares issuable upon the exercise of all of the Common Stock B Warrants issued pursuant to the Subscription Agreement (the "Stock Authorization"). The Company is obligated to effect the Stock Authorization no later than June 30, 2018 (the "Authorization Date"). The Common Stock B Warrants shall expire on the date that is two years after the Stock Authorization is effected (the "Expiration Date"). In the event that the Company fails to effect the Stock Authorization by the Authorization Date, the Expiration Date will be extended for two additional years. /s/ Megan N. Gates, attorney-in-fact 2018-04-16